Citations

Clear

6422 citation(s) found for "Su, Christopher".

Phenotypes and Trajectories of Tobacco-Exposed Persons with Preserved Spirometry: Insights from Lung Volumes
Arjomandi, Mehrdad , Zeng, Siyang , Bleecker, Eugene R., Bowler, Russell P. , Criner, Gerard J. , Comellas, Alejandro P. , Curtis, Jeffrey L. , Fortis, Spyridon , Hansel, Nadia N. , Hoffman, Eric A. , Kaner, Robert J., Kanner, Richard E. , Ortega, Victor E. , Peters, Stephen P. , Rennard, Stephen I. , Cooper, Christopher B., Tashkin, Donald P., Paine, Robert , Woodruff, Prescott G. , Bowler, Russell P , Comellas, Alejandro P , Curtis, Jeffrey L , Drummond, M Bradley , Fortis, Spyridon , Hoffman, Eric A , Krishnan, Jerry A , Criner, Gerard , Barjaktarević, Igor , Couper, David , Dransfield, Mark T. , Drummond, Michael , Han, MeiLan King , Labaki, Wassim W.

Mayo Clinic

Annals of the American Thoracic Society | November 25, 2024 | Volume: 22 | Issue: 4 | Pages: 494-505

10.1513/annalsats.202405-527oc | PMID 39586032 Get It

Abstract Rationale Among tobacco-exposed persons with preserved spirometry (TEPSs), we previously demonstrated that different lung volume indices—specifically, elevated total lung capacity (TLC) versus elevated ratio of functional residual capacity to TLC (FRC/TLC)—identify different lung disease characteristics in the COPDGene cohort. Objective We sought to determine differential disease characteristics and trajectories associated with lung volume indices among TEPSs in the SPIROMICS cohort. Methods We categorized TEPSs (n = 814) by tertiles (low, intermediate, and high) of TLC or residual volume–to-TLC ratio (RV/TLC) derived from baseline computed tomography images and then examined clinical and spirometric disease trajectories in mutually exclusive categories of participants with high TLC without high RV/TLC ([TLC]high) versus high RV/TLC without high TLC ([RV/TLC]high). We examined differences in computed tomography–measured emphysema (Hounsfield units [HU] ⩽−950; parametric response mapping [PRM] of emphysema), air trapping (HU⩽−856; PRM of functional small airway disease; a disease probability measure for non-emphysematous gas trapping), airway geometry (the mean square root of wall area of a hypothetical airway with 10 mm internal perimeter), respiratory symptoms (on the modified Medical Research Council Dyspnea Scale; COPD Assessment Test [CAT]; St. George’s Respiratory Questionnaire [SGRQ]; and Short Form-12 [SF12]), and outcomes (annualized exacerbation rate) between the two categories at baseline and over follow-up time up to 8.5 years, using regression modeling adjusted for age, sex, height, weight, and smoking status (current vs. former smoker) and burden (pack-years). Results In TEPSs, the pattern of spirometric disease progression differed between participants with [TLC]high and those with [RV/TLC]high: There was increased forced vital capacity with stable forced expiratory volume in 1 second in participants with [TLC]high, versus unchanged forced vital capacity but nominally decreased forced expiratory volume in 1 second in those with [RV/TLC]high. Compared with participants with [TLC]high, TEPSs with [RV/TLC]high had less emphysema (by HU ⩽−950) but more airway disease (by HU ⩽−856; PRM of functional small airway disease; disease probability measure for gas trapping, and mean square root of wall area of a hypothetical airway with 10 mm internal perimeter), more respiratory symptoms (on the modified Medical Research Council Dyspnea Scale, CAT, SGRQ, and SF12), and more severe exacerbations at baseline. Over an average follow-up of 4.1 ± 2.4 years (range = 0.5–8.5 yr), TEPSs with [RV/TLC]high also had a higher likelihood of developing more severe spirometric disease (preserved ratio impaired spirometry or Global Initiative for Chronic Obstructive Lung Disease Classification 2) and worsening of their respiratory symptoms (on the CAT and SGRQ). Although the incidence rates of respiratory exacerbations, hospitalizations, and mortality were not significantly different between the two categories over the follow-up period, TEPSs with [RV/TLC]high were more likely to have been prescribed a respiratory inhaler at their last follow-up visit. Conclusions In these TEPSs from the SPIROMICS cohort, lung volume stratification by TLC versus RV/TLC identifies two pre-COPD phenotypes with distinct respiratory symptoms, radiographic features, and clinical trajectories. The characteristics of these pre-COPD phenotypes match those previously described in the COPDGene cohort using TLC versus FRC/TLC stratification.
Spinoplastic Reconstruction Using Iliac Crest Vascularized Bone Graft following Sacral Ependymoma Resection
Reece, Edward M., Spronsen, Nicole Van , Jeger, Jonathan L. , Fullmer, Christopher, Abdulwadood, Isra , Meyer, Jenna , Ropper, Alexander E., Winocour, Sebastian, Bohl, Michael A. , Kalani, Maziyar A. , Van Spronsen, Nicole, Velluto, Calogero , Jeger, Jonathan L

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | November 25, 2024 | Volume: 12 | Issue: 11 | Pages: e6341

10.1097/gox.0000000000006341 | PMID 39600334 Get It

Summary: Sacral reconstruction post tumor resection has historically been executed with the placement of hardware or free tissue transfer. Reconstruction using a vascularized bone graft is an alternative that avoids the complications associated with hardware placement or free tissue transfer. This article describes the first documented case of spinoplastic reconstruction using an iliac crest vascularized bone graft (IC-VBG) after the resection of a sacral ependymoma. This is a case of a 17-year-old boy with a history of a sacral myxopapillary ependymoma. He presented to a local emergency department complaining of 6 months of urinary incontinence and progressive paresthesias affecting the left lower extremity. Magnetic resonance imaging was significant for a lesion located in the extradural spinal canal. Biopsy confirmed a myxopapillary ependymoma, World Health Organization grade II. The initial intervention involved tumor resection with titanium hardware placement. He subsequently required replacement of the titanium hardware with carbon fiber, secondary to the need for surveillance imaging. He underwent harvesting and inset of the IC-VBG at the time of hardware replacement. IC-VBG is a safe and effective modality for spinoplastic reconstruction. It enhances the potential for solid bony union and offers a practical alternative to free bone transfer. This approach provides an asset to add to a reconstructive surgeon’s armamentarium, making it an essential tool for reconstructive surgeons working in conjunction with spinal surgery colleagues.
Moving beyond tokenism: Sustaining engagement of persons living with dementia in identifying emergency research priorities
Sandoval, Jacqueline , Carpenter, Christopher R. , Shah, Manish N. , Dussetschleger, Jeffrey, Gil, Heidi, Jaspal, Naveena, Jobe, Deborah, Vann, Allan, Webb, Teresa, Hwang, Ula , Carpenter, Christopher R , Shah, Manish N , Hwang, Ula , Gilmore‐Bykovskyi, Andrea L , Dresden, Scott M. , Ellenbogen, Michael I.

Mayo Clinic

Journal of the American Geriatrics Society | November 22, 2024 | Volume: 73 | Issue: 5 | Pages: 1344-1352

10.1111/jgs.19269 | PMID 39576051 Get It

Abstract Introduction The Geriatric Emergency Care Applied Research Network 2.0‐Advancing Dementia Care (GEAR 2.0‐ADC) aims to advance research efforts to improve the emergency care of persons living with dementia (PLWDs). Objective To support this objective, GEAR 2.0‐ADC convened a virtual consensus conference to prioritize emergency care research opportunities for PLWDs inclusive of perspectives of PLWDs to ensure identification of research gaps in response to their experiences and priorities. Inclusion of PLWDs as research partners is increasingly recognized as a best practice, however, approaches to facilitating consensus participation are lacking. Methods Best practices for supporting the engagement of PLWDs in a consensus conference, applied across its three phases (pre‐conference, during the conference, and post‐conference), include: establishing a learning environment focused on research priorities before the event, presenting information in ways that align with participants' learning preferences while accommodating cognitive impairments, and providing multiple opportunities and methods for gathering post‐conference feedback from PLWDs. Results These strategies were identified by PLWDs and care partners (CPs) through semi‐structured interviews, who were involved in the convening process, aimed at exploring ways to enhance facilitation techniques for participants. Conclusion Additionally, these summarized insights aim to encourage the use of community‐engaged approaches in discussions and consensus‐building around research priorities in emergency care, particularly for PLWDs and their CPs.
American Society of Hematology: building a comprehensive minority recruitment and retention professional program
Rollins, Margo , Warsame, Rahma , Smith, Melody , Rouce, Rayne H. , Avalos, Belinda R. , Johnson, Cage S., López, José A. , Thompson, Alexis A. , Fanning, Lisa, Frustace, Patricia, Roche, Keelin F. , Havre, Nathalie van , Mack, Devon, Flowers, Christopher R. , Rollins, Margo R , Warsame, Rahma , Thompson, Alexis A , Terrell, Deirdra R , Smith, Melody , Molina, Arturo , Terrell, Deirdra R.

Mayo Clinic

Blood Advances | November 21, 2024 | Volume: 8 | Issue: 24 | Pages: 6237-6247

10.1182/bloodadvances.2024013519 | PMID 39570294 Get It

Abstract In 2003, the Institute of Medicine noted the need to improve workforce diversity. The American Society of Hematology (ASH) responded by developing the Minority Recruitment Initiative (MRI) to recruit diverse physicians/scientists into hematology. We evaluated the outcomes of the program. From 2004 to 2022, there were 405 awardees. Compared with national estimates, MRI awardees were less likely to discontinue their degree programs. MRI graduate student awardees had 0% attrition (97.5% confidence interval [CI], 10.6), whereas the national minority graduate student attrition was 36%. Medical student awardees had 2.2% (95% CI, 0.61-5.6) attrition, compared with the minority medical school attrition of 5.6%. Awardees were more likely than expected to pursue hematology-oncology (5.7% minority national estimate) because 14.4% (95% CI, 8.1-23.0) of medical student awardees and 88.5% (95% CI, 70.0-97.6) of early career awardees remain in the field. ASH has developed a successful program, but continued efforts are needed to advance equity in hematology.
Radiology-pathology correlation: Rosai–Dorfman disease
Benson, John C. , Pais, Alex B, Mark, Ian T. , Chen, John J. , Meyer, Frederic B., Giannini, Caterina, Tobin, William O, Benson, John , Mark, Ian , Chen, John J , Pais, Alex B, Tobin, W. Oliver , Hunt, Christopher H.

Mayo Clinic

The Neuroradiology Journal | November 20, 2024 | Volume: 38 | Issue: 3 | Pages: 299-303

10.1177/19714009241303077 | PMID 39567877 Get It

Rosai–Dorfman Disease (RDD), also known as sinus histiocytosis with massive lymphadenopathy, is a rare non-Langerhans cell histiocytic neoplasm. Although the disease classically presents as massive painless lymphadenopathy in young adults, RDD can also involve the central nervous system in some patients. CNS lesions, can cause headaches, neurologic deficits, and even neurologic deficits. The imaging appearance of CNS RDD typically mimics that of meningiomas: well-circumscribed dural-based lesions that often have dural tails. However, some imaging clues also exist that might help a radiologist recognize RDD, even before histopathologic confirmation. This radiology-pathology report of a patient with CNS RDD highlights the most pertinent clinical, imaging, and pathologic features of CNS RDD, and discusses what the neuroradiologist needs to know about the disease.
Positron emission tomography harmonization in the Alzheimer's Disease Neuroimaging Initiative: A scalable and rigorous approach to multisite amyloid and tau quantification
Landau, Susan, Baker, Suzanne L. , Boswell, Martin S., Lee, JiaQie, Taggett, Jacinda , Ward, Tyler J. , Chadwick, Trevor, Murphy, Alice, DeCarli, Charles, Jack, Clifford R. , Jagust, William J. , Initiative, for the U.S. POINTER Study Group and for the Alzheimer's Disease Neuroimaging, DeCarli, Charles , DeCarli, Charles , Jack, Clifford R , Harrison, Theresa M. , Schwarz, Christopher G. , Vemuri, Prashanthi , Koeppe, Robert A. , Initiative, for the U.S. POINTER Study Group and for the Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | November 19, 2024 | Volume: 21 | Issue: 1 | Pages: No page available

10.1002/alz.14378 | PMID 39559932 Get It

Abstract INTRODUCTION A key goal of the Alzheimer's Disease NeuroImaging Initiative (ADNI) positron emission tomography (PET) Core is to harmonize quantification of β‐amyloid (Aβ) and tau PET image data across multiple scanners and tracers. METHODS We developed an analysis pipeline (Berkeley PET Imaging Pipeline, B‐PIP) for ADNI Aβ and tau PET images and applied it to PET data from other multisite studies. Steps include image pre‐processing, refacing, magnetic resonance imaging (MRI)/PET co‐registration, visual quality control (QC), quantification of tracer uptake, and standardization of Aβ and tau standardized uptake value ratios (SUVrs) across tracers. RESULTS Measurements from 10,105 cross‐sectional and longitudinal Aβ and tau PET scans acquired in several studies between 2010 and 2024 can be processed, harmonized, and directly merged across tracers and cohorts. DISCUSSION The B‐PIP developed in ADNI is a scalable image harmonization approach used in several observational studies and clinical trials that facilitates rigorous Aβ and tau PET quantification and data sharing. Highlights Quantitative results from ADNI Aβ and tau PET data are generated using a rigorous, scalable image processing pipeline This pipeline has been applied to PET data from several other large, multisite studies and trials Quantitative outcomes are harmonizable across studies and are shared with the scientific community
Automatic responsiveness testing in epilepsy with wearable technology: The ARTiE Watch
Wheeler, Lydia , Křemen, Václav , Mersereau, Cole, Ornelas, Guillermo, Yadav, Taruna , Cormier, Devon, Derry, Allyson, Lopez, Andrea Duque , McQuown, Kevin, Sladky, Vladimir , Blumenfeld, Hal , Team, START Project Collaborative, Duque Lopez, Andrea M , Benjamin, Christopher , Worrell, Gregory A , Blumenfeld, Hal , Kremen, Vaclav , Giacino, Joseph T. , Team, START Project Collaborative, Worrell, Gregory

Mayo Clinic

Epilepsia | November 19, 2024 | Volume: 66 | Issue: 1 | Pages: 104-116

10.1111/epi.18181 | PMID 39559901 Get It

Abstract Objective An accurate evaluation of behavioral responsiveness during and after seizures in people with epilepsy is critical for diagnosis and management. Current methods for assessing behavioral responsiveness are characterized by substantial variation, subjectivity, and limited reliability and reproducibility in ambulatory and epilepsy monitoring unit settings. In this study, we aimed to develop and implement a novel mobile platform for deployment of automated responsiveness testing in epilepsy—the ARTiE Watch—to facilitate standardized, objective assessments of behavioral responsiveness during and after seizures. Methods We prospectively recruited patients admitted to the epilepsy monitoring units for diagnostic evaluation and long‐term video‐electroencephalographic monitoring at Mayo Clinic and Yale New Haven Hospital. Participants wore the ARTiE Watch, a smartwatch paired with custom smartphone software integrated with cloud infrastructure allowing for remote activation of standardized assessment on the participants' smartwatches. The assessment consisted of 18 command prompts that test behavioral responsiveness across motor, language, and memory domains. Upon visually identifying an electrographic seizure during EMU monitoring, the BrainRISE platform was used to deploy the ARTiE Watch behavioral testing sequence. Responsiveness scoring was conducted on smartwatch files. Results Eighteen of 56 participants had a total of 39 electrographic seizures assessed with the ARTiE Watch. The 18 subjects with ARTiE Watch‐tested seizures had a total of 67 baseline (interictal) ARTiE Watch tests collected for analysis. The analysis showed distinct ARTiE Watch behavioral responsiveness phenotypes: (1) decreased responsiveness across all ARTiE Watch commands during seizure (ictal–postictal) periods compared (to baseline ( p < .0001), (2) decreased responsiveness in bilateral tonic–clonic seizures compared to baseline ( p < .0001) and compared to focal seizures ( p < .0001), and (3) decreased responsiveness during focal impaired awareness seizures compared to baseline ( p < .0001) and compared to focal aware seizures ( p < .001). Significance ARTiE Watch behavioral testing deployed utilizing a mobile cloud‐based platform is feasible and can provide standardized, objective behavioral responsiveness assessments during seizures.
Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity
Zile, Michael R. , Borlaug, Barry A. , Kramer, Christopher M. , Baum, Seth J. , Litwin, Sheldon E. , Menon, Venu , Ou, Yang , Weerakkody, Govinda J. , Hurt, Karla, Murakami, Masahiro, Group, for the SUMMIT Trial Study, Murakami, Masahiro , Packer, Milton , Borlaug, Barry A , Zile, Michael R , Kanu, Chisom , Packer, Milton , Group, for the SUMMIT Trial Study

Mayo Clinic

Circulation | November 18, 2024 | Volume: 151 | Issue: 10 | Pages: 656-668

10.1161/circulationaha.124.072679 | PMID 39556714 Get It

BACKGROUND: Patients with heart failure with preserved ejection fraction and obesity have significant disability and frequent exacerbations of heart failure. We hypothesized that tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, would improve a comprehensive suite of clinical end points, including measures of health status, functional capacity, quality of life, exercise tolerance, patient well-being, and medication burden, in these patients. METHODS: We randomized (double-blind) 731 patients with class II to IV heart failure, ejection fraction ≥50%, and body mass index ≥30 kg/m 2 to tirzepatide (titrated up to 15 mg SC weekly; n=364) or placebo (n=367) added to background therapy for a median of 104 weeks (quartile 1, 66; quartile 3, 126 weeks). The primary end points were whether tirzepatide reduced the combined risk of cardiovascular death or worsening heart failure and improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score. The current expanded analysis included sensitivity analyses of the primary end points, 6-minute walk distance, EQ-5D-5L health state index, Patient Global Impression of Severity Overall Health score, New York Heart Association class, use of heart failure medications, and a hierarchical composite based on all-cause death, worsening heart failure, and 52-week changes in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score and 6-minute walk distance. RESULTS: Patients were 65.2±10.7 years of age; 53.8% (n=393) were female; body mass index was 38.2±6.7 kg/m 2 ; Kansas City Cardiomyopathy Questionnaire Clinical Summary Score was 53.5±18.5; 6-minute walk distance was 302.8±81.7 m; and 53% (n=388) had a worsening heart failure event in the previous 12 months. Compared with placebo, tirzepatide produced a consistent beneficial effect across all composites of death and worsening heart failure events, analyzed as time to first event (hazard ratios, 0.41–0.67). At 52 weeks, tirzepatide increased the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score by 6.9 points (95% CI, 3.3–10.6; P <0.001), 6-minute walk distance 18.3 meters (95% CI, 9.9–26.7; P <0.001), and EQ-5D-5L 0.06 (95% CI, 0.03–0.09; P <0.001). The tirzepatide group shifted to a more favorable Patient Global Impression of Severity Overall Health score (proportional odds ratio, 1.99 [95% CI, 1.44–2.76]) and New York Heart Association class (proportional odds ratio, 2.26 [95% CI, 1.54–3.31]; both P <0.001) and required fewer heart failure medications ( P =0.015). The broad spectrum of effects was reflected in benefits on the hierarchical composite (win ratio, 1.63 [95% CI, 1.17–2.28]; P =0.004). CONCLUSIONS: Tirzepatide produced a comprehensive, meaningful improvement in heart failure across multiple complementary domains; enhanced health status, quality of life, functional capacity, exercise tolerance, and well-being; and reduced symptoms and medication burden in patients with heart failure with preserved ejection fraction and obesity. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04847557.
Novel HMGA2::COL14A1 Fusion Identified in Xanthogranulomatous Epithelial Tumor/Keratin‐Positive Giant Cell Tumor
Dehner, Carina , Buehler, Darya, Hofich, Christopher, Halling, Kevin C. , Folpe, Andrew L. , Dehner, Carina A

Mayo Clinic

Genes, Chromosomes and Cancer | November 18, 2024 | Volume: 63 | Issue: 11 | Pages: No page available

10.1002/gcc.70010 | PMID 39552601 Get It

ABSTRACTXanthogranulomatous epithelial tumor (XGET)/Keratin‐positive giant cell tumor (KP‐GCT) represents a spectrum of recently described neoplasms characterized by a proliferation of distinctive mononuclear cells expressing keratin within a background of osteoclast‐like giant cells, mixed inflammatory cells, and a variably prominent xanthogranulomatous component. Recent studies demonstrated a recurrent HMGA2::NCOR2 fusion in many cases. We herein describe a case of XGET/KP‐GCT arising in the right femoral head of a 19‐year‐old male harboring a rare novel HMGA2::COL14A1 fusion.
Failed ulnar nerve surgery due to persistent unrecognized snapping triceps from cubitus varus due to a distal humeral malunion in an adult: illustrative case
O’Driscoll, Christopher J. L., Spinner, Robert J., O’Driscoll, Christopher J. L., Spinner, Robert J.

Mayo Clinic

Journal of Neurosurgery: Case Lessons | November 18, 2024 | Volume: 8 | Issue: 21 | Pages: No page available

10.3171/case24596 | PMID 39556818 Get It

BACKGROUND Snapping triceps is a dynamic condition in which a portion of the medial head of the triceps dislocates over the medial epicondyle during flexion or extension. Pushed by the triceps, the ulnar nerve typically also dislocates over the medial epicondyle, causing neuropathy. Posttraumatic cubitus varus deformities resulting from pediatric supracondylar fractures have been associated with snapping triceps. This is the first case of snapping triceps associated with cubitus varus due to distal humeral malunion, which occurred in an adult. OBSERVATIONS A 23-year-old man sustained a left distal humeral fracture from arm wrestling, which was treated nonoperatively, healing in a varus malunion. Within several months, he developed ulnar neuropathy and snapping at the medial elbow, which was diagnosed as a dislocating ulnar nerve and was treated with ulnar nerve transposition. He presented 8 years later with continued ulnar neuritis symptoms and snapping and was found to have snapping medial triceps. He chose nonoperative treatment. LESSONS Snapping triceps, presenting as snapping at the elbow with ulnar nerve symptoms, can be incorrectly diagnosed as isolated ulnar nerve dislocation. Unrecognized snapping triceps leads to persistent symptoms after ulnar nerve transposition. The patient in this case demonstrated that an altered triceps line of pull can cause snapping triceps regardless of how the cubitus varus originated. https://thejns.org/doi/10.3171/CASE24596